论文部分内容阅读
目的:观察表阿霉素大剂量持续静滴化疗的心脏毒性和安全性。方法:147例无心脏疾患的乳腺癌术后辅助化疗患者,按照病理分期应用常规剂量和方法化疗(Ⅱ期,对照组)及表阿霉素大剂量持续静滴化疗(Ⅲ期,观察组),连续6个周期,第2,4,6周期末和化疗后第3、6个月分别检查心电图、心功能评价和心脏超声检查心脏射血分数。观察组表阿霉素应用80mg/m2,持续24h静滴。结果:化疗第2周期末,心脏毒性反应几乎未发生。第4周期末开始,心脏毒性反应的发生率明显增加,并随着治疗周期的延长而增加。化疗停药后患者的心脏毒性逐渐下降,心功能恢复。观察组患者发生率的绝对值明显高于对照组,但两组间未见有统计学差异(p>0.05)。结论:表阿霉素大剂量持续静滴化疗的心脏毒性与常规剂量使用方法相当,安全性较高,患者能耐受。
OBJECTIVE: To observe the cardiotoxicity and safety of epirubicin in high-dose continuous intravenous chemotherapy. Methods: One hundred and seventy-seven patients with postoperative adjuvant chemotherapy without heart disease were treated with routine dose and chemotherapy (phase Ⅱ, control group) and epirubicin high-dose continuous intravenous chemotherapy (phase Ⅲ, observation group) , 6 consecutive cycles, at the end of 2, 4 and 6 cycles, and 3 and 6 months after chemotherapy, ECG, cardiac function evaluation and echocardiography were performed respectively. Epirubicin observation group 80mg / m2, continuous 24h intravenous infusion. Results: At the end of the second cycle of chemotherapy, cardiotoxicity hardly occurred. At the end of the fourth cycle, the incidence of cardiotoxic reactions increased significantly and increased with the duration of the treatment. Cardiac toxicity of patients after chemotherapy withdrawal decreased gradually, cardiac function recovered. The absolute incidence of observation group patients was significantly higher than the control group, but no significant difference between the two groups (p> 0.05). CONCLUSION: Cardiotoxicity of epirubicin at high dose with sustained intravenous chemotherapy is comparable to that of conventional dose, with higher safety and tolerability.